Wainger, B. J. *et al.* (2014) “Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons,” *Cell reports*, 7(1), pp. 1–11.

Wainger, B. J. *et al.* (2021) “Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial,” *JAMA neurology*, 78(2), pp. 186–196.

Wang, H. S. *et al.* (1998) “KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel,” *Science*. American Association for the Advancement of Science, 282(5395), pp. 1890–1893.

Wu, Z. *et al.* (2017) “Activation of KCNQ Channels Suppresses Spontaneous Activity in Dorsal Root Ganglion Neurons and Reduces Chronic Pain after Spinal Cord Injury,” *Journal of neurotrauma*, 34(6), pp. 1260–1270.


Xu, W. *et al.* (2010) “Activation of voltage-gated KCNQ/Kv7 channels by anticonvulsant retigabine attenuates mechanical allodynia of inflammatory temporomandibular joint in rats,” *Molecular pain*, 6, p. 49.

Zhang, F. *et al.* (2018) “Fragile X mental retardation protein modulates the stability of its m6A-marked messenger RNA targets,” *Human molecular genetics*. Oxford Academic, 27(22), pp. 3936–3950.

Zhao, G. *et al.* (2020) “Gene4Denovo: an integrated database and analytic platform for de novo mutations in humans,” *Nucleic acids research*. Oxford Academic, 48(D1), pp. D913–D926.

Summary

Provided herein is a pharmaceutical composition comprising a compound of formula (I’), or a solvate or a pharmaceutically acceptable salt thereof:




(I'),

wherein R^1, R^2, R^3, R^4, R^5, Y^1, Y^2, Y^3, n and R^6 are as defined herein.

The present disclosure provides compounds of formula (I'), or a solvate or a pharmaceutically acceptable salt thereof.

In one aspect, the present disclosure provides a compound of formula (I'), or a solvate or a pharmaceutically acceptable salt thereof:



(I')

wherein:

Y^1 is CR^a or N;

Y^2 is CR^b or N;

Y^3 is CR^c or N;

provided that only 0 or 1 of Y^1, Y^2 and Y^3 is N and the others are CR^a, CR^b, or CR^c;

R^a, R^b and R^c are each independently selected from hydrogen or halogen;

R^1 is selected from a 4-6 membered heterocycloalkyl, cyano, haloC_{1-6}alkoxy, haloC_{1-6} alkylthio, C_{1-6}alkoxy, a 4-6 membered heterocyclyloxy, 4-6 membered cycloalkyloxy, halogen, haloC_{1-6}alkyl, C_{3-5}cycloalkylC_{1-6}alkoxy, cyanoC_{1-6}alkoxy, and 5 membered heteroaryl; wherein the heterocycloalkyl, heterocyclyloxy, and heteroaryl are optionally substituted with one C_{1-6}alkyl, or haloC_{1-6}alkyl; wherein the 4-6 membered cycloalkyloxy is optionally substituted with one, two, or three substituents independently selected from halogen; and wherein the haloC_{1-6}alkoxy is optionally substituted with C_{1-6}alkoxy;

R^2 and R^3 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, a saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, and hydroxyC_{1-6}alkyl; or

R^2 and R^3 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;

R^4 and R^5 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, hydroxyC_{1-6}alkyl, haloC_{1-6}alkyl and hydroxy; or

R^4 and R^5 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;

R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, a 3-10 membered cycloalkyl, phenyl, C_{1-6}alkyl, haloC_{1-6}alkyl, haloC_{1-6}alkoxy and Si(C_{1-6}alkyl)$_3$; wherein the heterocycloalkyl, heteroaryl, cycloalkyl, or phenyl are optionally substituted with one, two, or three substituents independently selected from halogen, C_{1-6} alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, cyano, oxo, hydroxy, hydroxyC_{1-6}alkyl, haloC_{1-6}alkyl and C_{2-6} alkynyl; and


n is 0, 1, 2, or 3.

In a further aspect, the present disclosure provides a pharmaceutical composition comprising the compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, as described herein, wherein the pharmaceutical composition optionally further comprises one or more pharmaceutical excipients.


The present disclosure provides a process for the preparation of a compound of formula (I'), or a solvate or a pharmaceutically acceptable salt thereof.

In a further aspect, the present disclosure provides a process for the preparation of a compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, as described herein, wherein:


(i) the urea formation comprises the reactions:




or



or




or



wherein R^1, R^2, R^3, n, R^4, R^5 and R^6 are as defined herein,

optionally wherein R^1 is selected from 7-12 membered heterocycloalkyl, cyano, halogen, haloC_{1-6}alkyl, and 5 membered heteroaryl; or


(ii) the process comprises the following reaction step:



wherein R^1, R^2, R^3, n, R^4, R^5 and R^6 are as defined herein,

optionally wherein R^1 is selected from haloC_{1-6}alkoxy, C_{1-6}alkoxy, 4-6 membered heterocyclyloxy, and C_{3-5}cycloalkylC_{1-6}alkoxy and R^2 and R^3 are hydrogen; or

(iii) the process comprises the reactions of the following reaction steps:



wherein R^1, R^2, R^3, n, R^4, R^5 and R^6 are as defined herein,

optionally wherein R^1 is selected from haloC_{1-6}alkoxy, C_{1-6}alkoxy, 4-6 membered heterocyclyloxy, C_{3-5}cycloalkylC_{1-6}alkoxy, or cyanoC_{1-6}alkoxy, and R^2 is hydroxyC_{1-6}alkyl and R^3 is hydrogen.

The present disclosure provides a compound of formula (I'), or a solvate or a pharmaceutically acceptable salt, when manufactured according to a process described herein.

The present disclosure provides a compound of formula (I'), or a solvate or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, for use as therapeutically active substance.

The present disclosure provides a compound of formula (I') , or a solvate or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, for use in the therapeutic and/or prophylactic treatment of a disorder, disease, or disability associated with Kv7.2.

In a further aspect, the present disclosure provides a compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof as described herein, or a pharmaceutical composition as described herein, for use in the therapeutic and/or prophylactic treatment of a disorder, disease, or disability associated with Kv7.2 in a subject in need thereof, wherein the disorder, disease, or disability is selected from behavioral disorders, mood disorders, neurodevelopmental disorders, intellectual disability, epilepsies, neurodegenerative diseases, pain, migraine, and tinnitus.

In a further aspect, the present disclosure provides a compound as described herein, or a pharmaceutical composition as described herein, for use in therapy.

The present disclosure provides the use of a compound of formula (I'), or a solvate or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, in the therapeutic and/or prophylactic treatment of a disorder, disease, or disability associated with Kv7.2.

The present disclosure provides the use of a compound of formula (I'), or a solvate or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising

the same, for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of a disorder, disease, or disability associated with Kv7.2.

The present disclosure provides a method for the therapeutic and/or prophylactic treatment of a disorder, disease, or disability associated with Kv7.2, which method comprises administering a therapeutically effective amount of a compound of formula (I'), or a solvate or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.

The present disclosure provides a kit for use in the therapeutic and/or prophylactic treatment of a disorder, disease, or disability associated with Kv7.2, comprising:

a) a compound of formula (I'), or a solvate or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition or a pharmaceutical composition for use comprising the same; and
b) instructions for use.

In a further aspect, the present disclosure provides a kit for use in the therapeutic and/or prophylactic treatment of a disorder, disease, or disability associated with Kv7.2 comprising:

a) a compound as described herein, or a pharmaceutical composition as described herein; and
b) instructions for use;

wherein the disorder, disease or disability is selected from behavioral disorders, mood disorders, neurodevelopmental disorders, intellectual disability, epilepsies, neurodegenerative diseases, pain, migraine, and tinnitus.


In a further aspect, the present disclosure provides the disclosure as hereinbefore described.

The compounds of formula (I') , or a solvate or a pharmaceutically acceptable salts thereof, as described herein, provide for a combination of favorable pharmacological properties, such as for example potency, selectivity, and metabolic stability. A reasonable metabolic stability is important to ensure a suitable pharmacological half life, which is best achieved with compounds that have a human liver microsomal clearance below 20 uL/min/mg. Selectivity within the Kv7 family is desirable to avoid actions on tissues without therapeutic potential for the indications described in this disclosure. For example, actions on Kv7.4 and Kv7.5 in skeletal and smooth muscle impact the function of human arteries, where KCNQ2 expression is minimal or undetected in these tissues (Ng et al 2011).

The same examples as described above are included for a compound of formula (I), or a solvate or a pharmaceutically acceptable salt thereof:

CLAIMS

1. A compound of formula (I'), or a solvate or a pharmaceutically acceptable salt thereof:



(I')

wherein:

Y^1 is CR^a or N;

Y^2 is CR^b or N;

Y^3 is CR^c or N;

provided that only 0 or 1 of Y^1, Y^2 and Y^3 is N and the others are CR^a, CR^b, or CR^c;

R^a, R^b and R^c are each independently selected from hydrogen or halogen;

R^1 is selected from a 4-6 membered heterocycloalkyl, cyano, haloC_{1-6}alkoxy, haloC_{1-6} alkylthio, C_{1-6}alkoxy, a 4-6 membered heterocyclyloxy, 4-6 membered cycloalkyloxy, halogen, haloC_{1-6}alkyl, C_{3-5}cycloalkylC_{1-6}alkoxy, cyanoC_{1-6}alkoxy, and 5 membered heteroaryl; wherein the heterocycloalkyl, heterocyclyloxy, and heteroaryl are optionally substituted with one C_{1-6}alkyl, or haloC_{1-6}alkyl; wherein the 4-6 membered cycloalkyloxy is optionally substituted with one, two, or three substituents independently selected from halogen; and wherein the haloC_{1-6}alkoxy is optionally substituted with C_{1-6}alkoxy;

R^2 and R^3 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, a saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, and hydroxyC_{1-6}alkyl; or

R^2 and R^3 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;


R^4 and R^5 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, hydroxyC_{1-6}alkyl, haloC_{1-6}alkyl and hydroxy; or

R^4 and R^5 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;

R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, a 3-10 membered cycloalkyl, phenyl, C_{1-6}alkyl, haloC_{1-6}alkyl, haloC_{1-6}alkoxy and Si(C_{1-6}alkyl)$_3$; wherein the heterocycloalkyl, heteroaryl, cycloalkyl, or phenyl are optionally substituted with one, two, or three substituents independently selected from halogen, C_{1-6} alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, cyano, oxo, hydroxy, hydroxyC_{1-6}alkyl, haloC_{1-6}alkyl and C_{2-6} alkynyl; and

n is 0, 1, 2, or 3.

2. A compound according to claim 1 wherein the compound is of formula (I), or a solvate or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 is selected from a 4-6 membered heterocycloalkyl, cyano, haloC_{1-6}alkoxy, haloC_{1-6} alkylthio, C_{1-6}alkoxy, a 4-6 membered heterocyclyloxy, 4-6 membered cycloalkyloxy, halogen, haloC_{1-6}alkyl, C_{3-5}cycloalkylC_{1-6}alkoxy, cyanoC_{1-6}alkoxy, and 5 membered heteroaryl; wherein the heterocycloalkyl, heterocyclyloxy, and heteroaryl are optionally substituted with one C_{1-6}alkyl, or haloC_{1-6}alkyl; wherein the 4-6 membered cycloalkyloxy is optionally substituted with one, two, or three substituents independently selected from halogen; and wherein the haloC_{1-6}alkoxy is optionally substituted with C_{1-6}alkoxy;

R^2 and R^3 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, a saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, and hydroxyC_{1-6}alkyl; or

R^2 and R^3 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;


R^4 and R^5 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, hydroxyC_{1-6}alkyl, haloC_{1-6}alkyl and hydroxy; or

R^4 and R^5 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;

R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, a 3-10 membered cycloalkyl, phenyl, C_{1-6}alkyl, haloC_{1-6}alkyl, haloC_{1-6}alkoxy and Si(C_{1-6}alkyl)$_3$; wherein the heterocycloalkyl, heteroaryl, cycloalkyl, or phenyl are optionally substituted with one, two, or three substituents independently selected from halogen, C_{1-6} alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, cyano, oxo, hydroxy, hydroxyC_{1-6}alkyl, haloC_{1-6}alkyl and C_{2-6} alkynyl; and

n is 0, 1, 2, or 3.

3. A compound according to claim 2, wherein the compound is of formula (I), or a solvate or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 is selected from a 4-6 membered heterocycloalkyl, cyano, haloC_{1-6}alkoxy, C_{1-6}alkoxy, a 4-6 membered heterocyclyloxy, halogen, haloC_{1-6}alkyl, C_{3-5}cycloalkylC_{1-6}alkoxy, cyanoC_{1-6}alkoxy, and 5 membered heteroaryl; wherein the heterocycloalkyl, heterocyclyloxy, and heteroaryl are optionally substituted with one C_{1-6}alkyl, or haloC_{1-6}alkyl;

R^2 and R^3 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, a saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, and hydroxyC_{1-6}alkyl; or

R^2 and R^3 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;

R^4 and R^5 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, hydroxyC_{1-6}alkyl, and hydroxy; or

R^4 and R^5 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;

R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, a 4-10 membered cycloalkyl, phenyl, C_{1-6}alkyl, and haloC_{1-6}alkyl; wherein the heterocycloalkyl, heteroaryl, cycloalkyl, or phenyl are optionally substituted with one, two, or three substituents independently selected from halogen, C_{1-6} alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, cyano, oxo, hydroxy, hydroxyC_{1-6}alkyl, and haloC_{1-6}alkyl; and

n is 0, 1, 2, or 3.

4. A compound of formula (I'), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 1 wherein:

Y^1, Y^2 are CH;

Y^3 is selected from CH or N.

5. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 4, wherein:

(i) R^1 is selected from cyano, haloC_{1-6}alkoxy, haloC_{1-6} alkylthio, a 4-6 membered heterocyclyloxy, halogen, haloC_{1-6}alkyl, C_{3-5}cycloalkylC_{1-6}alkoxy, and cyanoC_{1-6}alkoxy; wherein the heterocyclyloxy and cycloakylalkoxy are optionally substituted with one C_{1-6}alkyl or haloC_{1-6}alkyl; or

(ii) R^1 is selected from cyano, haloC_{1-6}alkoxy, haloC_{1-6} alkylthio, and haloC_{1-6}alkyl; or

(iii) R^1 is selected from cyano, CHF_2O-, CHF_2S-, CH_3CF_2O-, CH_3CFHCH_2O-, CF_3CH_2O-, CH_3CF_2-, CHF_2-, and CF_3-; or

(iv) R^1 is selected from CHF_2O-, CHF_2S-, CH_3CF_2O-, CH_3CFHCH_2O-, and CF_3CH_2O-; or

(v) R^1 is CHF_2O- or CH_3CF_2O-; or

(vi) R^1 is 5 membered heteroaryl selected from pyrazolyl and imidazolyl which are optionally substituted with one, two, or three substituents independently selected from halogen or haloC_{1-6}alkyl; or

(vii) R^1 is unsubstituted pyrazolyl or unsubstituted imidazolyl.

6. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, wherein:

(i) both R^2 and R^3 are hydrogen, or one of R^2 and R^3 is hydrogen and the other one is hydroxyC_{1-6}alkyl; or

(ii) one of R^2 and R^3 is hydrogen and the other one is hydroxyC_{1-6}alkyl selected from $HOCH_2$-, $HOCH_2CH_2$-, $HOCH_2CH_2CH_2$-, and $HOCH_2CH_2CH_2CH_2$-; or

(iii) one of R^2 and R^3 is hydrogen and the other one is $HOCH_2$- or $HOCH_2CH_2$-; or

(iv) both R^2 and R^3 are hydrogen.

7. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 6, wherein:

(i) n is 0 or 1; or

(ii) n is 0; or

(iii) n is 1; or

(iv) n is 1 and both R^4 and R^5 are hydrogen; or

(v) n is 1, and one of R^4 and R^5 is hydrogen and the other one is C_{1-6}alkyl, haloC_{1-6}alkyl, a saturated monocyclic 3-5 membered cycloalkyl, or C_{1-6}alkoxy; or

(vi) n is 1, and one of R^4 and R^5 is hydrogen and the other one is a methyl (CH_3-) or methoxy (CH_3O-); or

(vii) n is 1, and one of R^4 and R^5 is hydrogen and the other one is a trifluoromethyl (-CF_3) or difluoromethyl (-CHF_2); or

(viii) n is 1, and one of R^4 and R^5 is hydrogen and the other one is a saturated monocyclic 3-5 membered cycloalkyl which is unsubstituted cyclopropyl; or

(ix) R^4 and R^5, together with the one carbon atom to which they are attached, form cyclopropyl; or

(x) n is 1, and R^4 and R^5, together with the one carbon atom to which they are attached, form cyclopropyl.

8. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein:

(i) R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, a 3-10 membered cycloalkyl, C_{1-6}alkyl, haloC_{1-6}alkyl, Si(C_{1-6}alkyl)$_3$ and phenyl; wherein the heterocycloalkyl, heteroaryl, cycloalkyl, or phenyl are optionally substituted with one, two, or three substituents independently selected from halogen, C_{1-6} alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, cyano, oxo, hydroxy, hydroxyC_{1-6}alkyl, and haloC_{1-6}alkyl; or

(ii) R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, and a 3-10 membered cycloalkyl; wherein the heterocycloalkyl, heteroaryl, or cycloalkyl are optionally substituted with one, two, or three substituents independently selected from halogen, C_{1-6} alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, cyano, oxo, hydroxy, hydroxyC_{1-6}alkyl, and haloC_{1-6}alkyl; or

(iii) R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, and a 3-10 membered cycloalkyl; wherein the heterocycloalkyl, heteroaryl, or cycloalkyl are optionally substituted with one, two, or three substituents independently selected from Cl-, F-, CH_3-, CH_2F-, CF_3-, $(CH_3)_2CF$-, cyclopropyl, and CH_3O-, CF_3O-, CHF_2O-, cyano, and hydroxy; or

(iv) R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, and a 3-10 membered cycloalkyl; wherein the heterocycloalkyl, heteroaryl, or cycloalkyl are optionally substituted with one, two, or three substituents independently selected from Cl-, F-, CH_3-, CF_3-, cyclopropyl, CH_3O-, CF_3O- and CHF_2O-; or

(v) R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, and a 3-10 membered cycloalkyl; wherein the heterocycloalkyl, heteroaryl, or cycloalkyl are

optionally substituted with one, two, or three substituents independently selected from F-, CF_3-, CF_3O- and CHF_2O-; or

(vi) R^6 is selected from:

a) a 5-12 membered heterocycloalkyl, which heterocycloalkyl is selected from a 7-10 membered bicyclic edge-to-edge fused heterocycloalkyl comprising one aliphatic and one aromatic ring, wherein one ring comprises one O-atom; a 7-10 membered bicyclic edge-to-edge fused heterocycloalkyl comprising two aliphatic rings, wherein the one ring comprises one O-atom or one N-atom; and a 7-10 membered bridged heterocycloalkyl, wherein the bridge comprises an O-atom;

b) a 6 membered heteroaryl;

c) a 3-10 membered cycloalkyl selected from a saturated monocyclic 3-6 membered cycloalkyl, a 6 membered cycloalkenyl, a 4-10 membered bridged cycloalkyl, and a 7-10 membered bicyclic edge-to-edge fused cycloalkyl comprising two aliphatic rings;

d) phenyl;

e) $C_{1\text{-}6}$alkyl;

f) halo$C_{1\text{-}6}$alkyl;

g) Si($C_{1\text{-}6}$alkyl)$_3$; and

said R^6 is optionally substituted as defined in any one of the above options (i) to (v); or

(vii) R^6 is selected from:

a) a 5-12 membered heterocycloalkyl, which heterocycloalkyl is selected from a 7-10 membered bicyclic edge-to-edge fused heterocycloalkyl comprising one aliphatic and one aromatic ring, wherein one ring comprises one O-atom; a 7-10 membered bicyclic edge-to-edge fused heterocycloalkyl comprising two aliphatic rings, wherein the one ring comprises one O-atom or one N-atom; and a 7-10 membered bridged heterocycloalkyl, wherein the bridge comprises an O-atom;

b) a 6 membered heteroaryl; and

c) a 3-10 membered cycloalkyl selected from a saturated monocyclic 3-6 membered cycloalkyl, a 4-10 membered bridged cycloalkyl, and a 7-10 membered bicyclic edge-to-edge fused cycloalkyl comprising two aliphatic rings; or


(viii) R^6 is selected from:


dihydrochromenyl, cyclopentyl, phenyl, cyclohexyl, bicyclo[1.1.1]pentanyl, bicyclo[2.2.1]heptanyl, cyclohexenyl, cyclobutyl, tert-butyl, bicyclo[2.2.2]octanyl, $(CH_3)_2CF$-, CHF_2-, $Si(CH_3)_3$, bicyclo[3.1.0]hexanyl, oxolanyl, octahydropentalenyl, hexahydrocyclopenta[b]furanyl, pyrazinyl, pyridinyl, and pyrimidinyl; or


(ix) R^6 is selected from:

dihydrochromenyl, cyclopentyl, phenyl, cyclohexyl, bicyclo[1.1.1]pentanyl, bicyclo[2.2.1]heptanyl, cyclohexenyl, cyclobutyl, bicyclo[2.2.2]octanyl, bicyclo[3.1.0]hexanyl, oxolanyl, octahydropentalenyl, hexahydrocyclopenta[b]furanyl, pyrazinyl, pyridinyl, and pyrimidinyl; or


(x) R^6 is selected from:







(xi) R^6 is selected from:



and .

9. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 4, wherein R^1 is selected from CHF_2O-, unsubstituted pyrazolyl, unsubstituted imidazolyl, CH_3O-, $(CH_3)CF_2$-, CN-, CHF_2-, CF_3-, CF_3CH_2O-, CH_3CFHCH_2O-, CF_2H-S-, R^2 and R^3 are hydrogen, n is 0 or 1, (i) R^4 and R^5 are hydrogen, or (ii) one of R^4 and R^5 is hydrogen and the other is cyclopropyl, or (iii) one of R^4 and R^5 is hydrogen and the other is selected from CF_3-, CHF_2, and CH_2F or (iv) R^4 and R^5

together with the one carbon atom to which they are attached, form cyclopropyl, and R^6 is selected from a 5-12 membered heterocycloalkyl which heterocycloalkyl is a bicyclic edge-to-edge fused heterocycloalkyl comprising one aliphatic and one aromatic ring, wherein one ring comprises one O-atom, a 7-10 membered bicyclic edge-to-edge fused heterocycloalkyl comprising two aliphatic rings, wherein the one ring comprises one O-atom or one N-atom, a 7-10 membered bridged heterosystem, wherein the bridge comprises an O-atom, a 6 membered heteroaryl; and a 3-10 membered cycloalkyl selected from cyclopropyl, a saturated monocyclic 4-6 membered cycloalkyl, a 4-10 membered bridged cycloalkyl, and a 7-10 membered bicyclic edge-to-edge fused cycloalkyl comprising two aliphatic rings, all optionally substituted with:

- one, two, or three substituents independently selected from halogen, C_{1-6} alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, cyano, oxo, hydroxy, hydroxyC_{1-6}alkyl, and haloC_{1-6}alkyl; or

- one, two, or three substituents independently selected from Cl-, F-, CH_3-, CH_2F-, CF_3-, $(CH_3)_2CF$-, cyclopropyl, and CH_3O-, CF_3O-, CHF_2O-, cyano, and hydroxy; or

- one, two, or three substituents independently selected from Cl-, F-, CH_3-, CF_3-, cyclopropyl, CH_3O-, CF_3O- and CHF_2O-; or

- one, two, or three substituents independently selected from F-, CF_3-, CF_3O- and CHF_2O-;

preferably wherein: R^1 is selected from CF_3CH_2O-, CHF_2O- or unsubstituted imidazolyl, R^2 and R^3 are hydrogen, n is 0 or 1, (i) R^4 and R^5 are hydrogen, or (ii) one of R^4 and R^5 are hydrogen and the other is cyclopropyl, or (iii) one of R^4 and R^5 is hydrogen and the other is selected from CF_3-, CHF_2, and CH_2F, or (iii) R^4 and R^5 together with the one carbon atom to which they are attached, form cyclopropyl, and R^6 is selected from a 5-12 membered heterocycloalkyl which heterocycloalkyl is a bicyclic edge-to-edge fused heterocycloalkyl comprising one aliphatic and one aromatic ring, wherein one ring comprises one O-atom, a 7-10 membered bicyclic edge-to-edge fused heterocycloalkyl comprising two aliphatic rings, wherein the one ring comprises one O-atom or one N-atom, a 7-10 membered bridged heterosystem, wherein the bridge comprises an O-atom; a 6 membered heteroaryl; and a 3-10 membered cycloalkyl selected from cyclopropyl, a saturated monocyclic 4-6 membered cycloalkyl, a 4-10 membered bridged cycloalkyl, and a 7-10 membered bicyclic

edge-to-edge fused cycloalkyl comprising two aliphatic rings, all optionally substituted as defined above;

more preferably wherein: R^1 is selected from CF_3CH_2O-, CHF_2O- and unsubstituted imidazolyl, R^2 and R^3 are hydrogen, n is 0; and R^6 is selected from a 5-12 membered heterocycloalkyl which heterocycloalkyl is a bicyclic edge-to-edge fused heterocycloalkyl comprising one aliphatic and one aromatic ring, wherein one ring comprises one O-atom, a 7-10 membered bicyclic edge-to-edge fused heterocycloalkyl comprising two aliphatic rings, wherein the one ring comprises one O-atom or one N-atom, a 7-10 membered bridged heterosystem, wherein the bridge comprises an O-atom; a 6 membered heteroaryl; and a 3-10 membered cycloalkyl selected from cyclopropyl, a saturated monocyclic 4-6 membered cycloalkyl, a 4-10 membered bridged cycloalkyl, and a 7-10 membered bicyclic edge-to-edge fused cycloalkyl comprising two aliphatic rings; all optionally substituted as defined above;






even more preferably wherein: R^1 is CF_3CH_2O-, or CHF_2O- and R^6 is substituted with one or two F- or CF_3-, or R^6 is CF_3-;






even more preferably wherein: R^1 is CHF_2O- and R^6 is selected from a saturated monocyclic 4-6 membered cycloalkyl, a 4-10 membered bridged cycloalkyl, and a 7-10 membered bicyclic edge-to-edge fused cycloalkyl comprising two aliphatic rings; all substituted with one or two F- or CF_3-;






even more preferably wherein: R^1 is CHF_2O-, n is 0 or 1, and R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, and a 4-10 membered cycloalkyl; all substituted with substituted with one or two F- or CF_3-;





even more preferably wherein: R^1 is CHF_2O-, n is 0 or 1, and R^6 is selected from a saturated monocyclic 4-6 membered cycloalkyl, a 4-10 membered bridged cycloalkyl, and a 7-10 membered bicyclic edge-to-edge fused cycloalkyl comprising two aliphatic rings; all substituted with one or two F- or CF_3-.





10. A compound of formula (I'), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 1, wherein the compound is selected from:






Example	Name	Structure
1	1-[(4R)-3,4-dihydro-2H-chromen-4-yl]-3-[(2-pyrazol-1-ylpyridin-4-yl)methyl]urea	
2	1-cyclopentyl-3-[(2-pyrazol-1-ylpyridin-4-yl)methyl]urea	
4	1-(3-chlorophenyl)-3-[(2-pyrazol-1-ylpyridin-4-yl)methyl]urea	
5	1-[(2-cyanopyridin-4-yl)methyl]-3-(2,4,4-trimethylcyclohexyl)urea	
6	1-[(2-pyrazol-1-ylpyridin-4-yl)methyl]-3-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentanyl]urea	





Example	Name	Structure
7	1-[(2-pyrazol-1-ylpyridin-4-yl)methyl]-3-[rac-(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]urea	
8	1-(3-cyclopropylcyclohexyl)-3-[(2-imidazol-1-ylpyridin-4-yl)methyl]urea	
9	1-[(2-imidazol-1-ylpyridin-4-yl)methyl]-3-(2,4,4-trimethylcyclohexyl)urea	
10	1-[2-(cyclohexen-1-yl)ethyl]-3-[(2-pyrazol-1-ylpyridin-4-yl)methyl]urea	
12	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2R,4S)-2-	






Example	Name	Structure
	bicyclo[2.2.1]heptanyl]urea	
13	1-(cyclobutylmethyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
14	1-[(2-methoxypyridin-4-yl)methyl]-3-[rac-(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]urea	
15	1-[(1S,2S,4R)-2-bicyclo[2.2.1]heptanyl]-3-[(2-pyrazol-1-ylpyridin-4-yl)methyl]urea	
16	1-[(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]-3-[(2-pyrazol-1-ylpyridin-4-yl)methyl]urea	
17	1-(1-cyclobutylethyl)-	





Example	Name	Structure
	3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
18	1-(4,4-dimethylcyclohexyl)-3-[[2-(oxetan-3-yloxy)pyridin-4-yl]methyl]urea	
20	1-cyclopentyl-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
21	1-(cyclobutylmethyl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
22	1-(3-chlorophenyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	






Example	Name	Structure
23	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(4R)-3,4-dihydro-2H-chromen-4-yl]urea	
24	1-[1-(2-bicyclo[2.2.1]heptanyl)ethyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
25	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(2,6-dimethylcyclohexyl)urea	
26	1-[rac-(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]-3-[[2-[4-(trifluoromethyl)imidazol-1-yl]pyridin-4-yl]methyl]urea	





Example	Name	Structure
27	1-[(2-bromopyridin-4-yl)methyl]-3-[rac-(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]urea	
28	1-[[2-(1,3-oxazol-5-yl)pyridin-4-yl]methyl]-3-[rac-(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]urea	
29	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(2,2-dimethylpropyl)urea	
31	1-(1-bicyclo[1.1.1]pentanylmethyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
32	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(3-fluoro-1-	





Example	Name	Structure
	bicyclo[1.1.1]pentanyl)methyl]urea	
33	1-[[2-(1,1-difluoroethyl)pyridin-4-yl]methyl]-3-[rac-(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]urea	
34	1-[(2-cyanopyridin-4-yl)methyl]-3-[rac-(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]urea	
35	1-[[2-(difluoromethyl)pyridin-4-yl]methyl]-3-[rac-(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]urea	
36	1-[rac-(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]-3-[[2-(trifluoromethyl)p	






Example	Name	Structure
	yridin-4-yl]methyl]urea	
37	1-(4,4-dimethylcyclohexyl)-3-[(2-imidazol-1-ylpyridin-4-yl)methyl]urea	
38	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1-methoxycyclobutyl)methyl]urea	
39	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(2-fluoro-2-methylpropyl)urea	
40	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1-fluorocyclobutyl)methyl]urea	
41	1-(cyclobutylmethyl)-3-[[2-[4-	





Example	Name	Structure
	(trifluoromethyl)imidazol-1-yl]pyridin-4-yl]methyl]urea	
42	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
43	1-cyclopentyl-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
44	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[1-(2,2-dimethylpropyl)cyclopropyl]urea	
45	1-cyclobutyl-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
46	1-(cyclopentylmethyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
47	1-(1-bicyclo[1.1.1]pentanyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
48	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(4-fluoro-1-bicyclo[2.2.2]octanyl)urea	
49	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3-methoxy-1-bicyclo[1.1.1]pentanyl)urea	
50	1-(1-cyclobutylcyclopropyl)-3-[[2-	





Example	Name	Structure
	(difluoromethoxy) pyridin-4-yl]methyl]urea	
54	1-[[2-(cyclobutylmethoxy)pyridin-4-yl]methyl]-3-[(1*r*,3*r*)-3-(trifluoromethyl)cyclobutyl]urea	
55	1-[[2-(cyclopropylmethoxy)pyridin-4-yl]methyl]-3-[(1*r*,3*r*)-3-(trifluoromethyl)cyclobutyl]urea	
56	1-[[2-(2,2-difluoroethoxy)pyridin-4-yl]methyl]-3-[(1*r*,3*r*)-3-(trifluoromethyl)cyclobutyl]urea	
57	1-[[2-(1,1-difluoroethyl)pyridin-4-yl]methyl]-3-[(1*r*,3*r*)-3-	





Example	Name	Structure
	(trifluoromethyl)cyclobutyl]urea	
58	1-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]-3-[[2-(trifluoromethyl)pyridin-4-yl]methyl]urea	
59	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,3S)-3-(trifluoromethyl)cyclopentyl]urea	
60	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3-ethylcyclobutyl)urea	
62	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[[3-(trifluoromethyl)cyclobutyl]methyl]urea	





Example	Name	Structure
63	1-[[2-(cyanomethoxy)pyridin-4-yl]methyl]-3-[(1*r*,3*r*)-3-(trifluoromethyl)cyclobutyl]urea	
64	1-[[2-(2,2,2-trifluoroethyl)pyridin-4-yl]methyl]-3-[(1*r*,3*r*)-3-(trifluoromethyl)cyclobutyl]urea	
65	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3-methylcyclobutyl)urea	
66	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3-ethynylcyclobutyl)urea	
67	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-((1*r*,3*r*)-3-	





Example	Name	Structure
	fluorocyclobutyl)urea	
68	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[4-(trifluoromethyl)-1-bicyclo[2.2.2]octanyl]urea	
71	1-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]-3-[[3-(trifluoromethyl)cyclobutyl]methyl]urea	
73	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,5R)-6,6-difluoro-2-bicyclo[3.1.0]hexanyl]urea	
74	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-	




Example	Name	Structure
	(1R,5S)-6,6-difluoro-3-bicyclo[3.1.0]hexanyl]urea	
75	1-[(3-fluoro-1-bicyclo[1.1.1]pentanyl)methyl]-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
76	1-[(1R,3aR,6aR)-1,2,3,3a,4,5,6,6a-octahydropentalen-1-yl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
77	1-(3-cyclopropylcyclobutyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
78	1-(1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl)-3-[[2-(difluoromethoxy)	





Example	Name	Structure
	pyridin-4-yl]methyl]urea	
79	1-[rac-(1R,3S)-3-(trifluoromethyl)cyclopentyl]-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
81	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2S)-2-hydroxy-3,3-dimethylcyclobutyl]urea	
82	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(4-fluoro-2-hydroxy-1-bicyclo[2.2.2]octanyl)urea	
83	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3-	




Example	Name	Structure
	methoxyphenyl)urea	
84	1-(6-chloropyridin-2-yl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
85	1-[1-[2-(difluoromethoxy)pyridin-4-yl]-2-hydroxyethyl]-3-(4-fluoro-1-bicyclo[2.2.2]octanyl)urea	
87	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[[3-(1r,3r)-(trifluoromethyl)cyclobutyl]methyl]urea	
88	1-(4-fluoro-1-bicyclo[2.2.2]octanyl)-3-[[2-(2-fluoropropoxy)pyr	





Example	Name	Structure
	idin-4-yl]methyl]urea	
89	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(3-fluorocyclobutyl)methyl]urea	
90	1-(4,4-difluorocyclohexyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
91	1-[1-[2-(difluoromethoxy)pyridin-4-yl]-2-hydroxyethyl]-3-[(1*r*,3*r*)-3-(trifluoromethyl)cyclobutyl]urea	
92	1-(3-chlorophenyl)-3-[2-hydroxy-1-[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]ethyl]urea	





Example	Name	Structure
93	1-(3,3-difluorocyclopentyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
95	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(2-hydroxy-3,3-dimethylbutyl)urea	
96	1-(4-chloropyrimidin-2-yl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
97	1-(3-chlorophenyl)-3-[1-[2-(difluoromethoxy)pyridin-4-yl]-2-hydroxyethyl]urea	





Example	Name	Structure
98	1-(6-chloropyrazin-2-yl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
99	1-[rac-(1R,2S)-2-hydroxy-3,3-dimethylcyclobutyl]-3-[[2-[4-(trifluoromethyl)imidazol-1-yl]pyridin-4-yl]methyl]urea	
100	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1s,3s)-3-hydroxy-3-(trifluoromethyl)cyclobutyl]urea	





Example	Name	Structure
101	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2R)-2-hydroxy-5,5-dimethylcyclohexyl]urea	
102	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2S,4S)-7-oxabicyclo[2.2.1]heptan-2-yl]urea	
103	1-[(1S,3aS,6aS)-1,2,3,3a,4,5,6,6a-octahydropentalen-1-yl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
105	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(3aR,6aS)-1,2,3,3a,4,5,6,6a-	





Example	Name	Structure
	octahydropentalen-2-yl]urea	
106	1-(1-cyclopropyl-2,2,2-trifluoroethyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
107	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2S,4S,6R)-6-hydroxy-2-bicyclo[2.2.1]heptanyl]urea	
108	1-(3,3-difluorocyclobutyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
109	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3,3-dimethylbutyl)urea	
110	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[1-(2,2,2-trifluoroethyl)cyclopropyl]urea	
111	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,5S,6S,7R)-7-hydroxy-6-bicyclo[3.2.0]heptanyl]urea	
112	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(2R,3aS,6aS)-6a-(hydroxymethyl)-2,3,3a,4,5,6-	





Example	Name	Structure
	hexahydro-1H-pentalen-2-yl]urea	
113	1-(2,2-difluorocyclopentyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
114	1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
115	1-[(1R)-3,3-difluorocyclopentyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
116	1-[(1S)-3,3-difluorocyclopentyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
117	1-[1-[2-(difluoromethoxy)pyridin-4-yl]-3-hydroxypropyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
118	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2S)-2-hydroxycyclopentyl]urea	
119	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3,3,3-trifluoro-2-methoxypropyl)urea	
120	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[[rac-(3aR,6aR)-2,3,3a,4,5,6-hexahydrocyclope	




Example	Name	Structure
	nta[b]furan-6a-yl]methyl]urea	
121	1-[[2-(2,2-difluoropropoxy)pyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
122	1-[[2-(2,2-difluoropropoxy)pyridin-4-yl]methyl]-3-(4-fluoro-1-bicyclo[2.2.2]octanyl)urea	
123	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2S)-2-fluorocyclobutyl]urea	
125	1-[cyclobutyl(dideuterio)methyl]-3-[[2-(difluoromethoxy)	





Example	Name	Structure
	pyridin-4-yl]methyl]urea	
126	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3-methylphenyl)urea	
128	1-[(2-methoxypyridin-4-yl)methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
129	1-(4-fluoro-1-bicyclo[2.2.2]octanyl)-3-[(2-methoxypyridin-4-yl)methyl]urea	
131	1-(1-bicyclo[2.2.2]octanyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
132	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[3-(fluoromethyl)phenyl]urea	
133	1-[(1R,2R,5R)-6,6-difluoro-2-bicyclo[3.1.0]hexanyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
134	1-[(1R)-1-cyclopropyl-2,2,2-trifluoroethyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
135	1-[(1S)-1-cyclopropyl-2,2,2-trifluoroethyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
136	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[3-(difluoromethyl)cyclobutyl]urea	
137	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1s,3s)-3-(difluoromethyl)cyclobutyl]urea	
138	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,3S)-3-(trifluoromethyl)cyclohexyl]urea	
139	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,5S)-3-oxo-8-bicyclo[3.2.1]octanyl]urea	





Example	Name	Structure
140	1-[(1S)-3,3-difluorocyclohexyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
142	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3,3-difluoro-1-methylcyclopentyl)urea	
143	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(4,4-difluoro-1-methylcyclohexyl)urea	
144	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1S,3R)-3-(trifluoromethyl)cyclopentyl]urea	





Example	Name	Structure
145	1-(3-chlorophenyl)-3-[(1R)-2-hydroxy-1-[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]ethyl]urea	
146	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1R,3S)-3-(trifluoromethyl)cyclopentyl]urea	
147	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[2-hydroxy-2-(trifluoromethyl)cyclohexyl]urea	





Example	Name	Structure
148	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2R)-2-hydroxy-2-methylcyclohexyl]urea	
149	1-[(1R)-3,3-difluorocyclohexyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
150	1-(3-chloro-2-fluorophenyl)-3-[2-hydroxy-1-[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]ethyl]urea	
151	1-(4-fluoro-1-bicyclo[2.2.2]octanyl)-3-[[2-[(2R)-2-fluoropropoxy]pyr	




Example	Name	Structure
	idin-4-yl]methyl]urea	
152	1-(1-cyclobutyl-2,2,2-trifluoroethyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
153	1-(3-fluoro-1-bicyclo[1.1.1]pentanyl)-3-[[2-(trifluoromethyl)pyridin-4-yl]methyl]urea	
154	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2R)-4,4-difluoro-2-hydroxycyclohexyl]urea	
156	1-(4-fluoro-1-bicyclo[2.2.2]octanyl)-3-[[2-[(2S)-2-fluoropropoxy]pyr	


Example	Name	Structure
	idin-4-yl]methyl]urea	
157	1-(3,3-difluorocyclobutyl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
159	1-(3-fluoro-1-bicyclo[1.1.1]pentanyl)-3-[[2-(2,2,2-trifluoroethyl)pyridin-4-yl]methyl]urea	
160	1-(3-fluoro-1-bicyclo[1.1.1]pentanyl)-3-[[2-(2-fluoropropoxy)pyridin-4-yl]methyl]urea	
161	1-(5-chloropyridin-3-yl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
162	1-((1r,3r)-3-fluorocyclobutyl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
163	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-((1r,3r)-3-methylcyclobutyl)urea	
164	1-(3-chlorophenyl)-3-[[2-(fluoromethoxy)pyridin-4-yl]methyl]urea	
165	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,4R)-5,5-difluoro-2-bicyclo[2.2.1]heptanyl]urea	





Example	Name	Structure
166	1-(5-cyclopropyloxolan-3-yl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
168	1-(3-fluoro-1-bicyclo[1.1.1]pentanyl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
169	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,5S)-6,6-difluoro-3-bicyclo[3.1.0]hexanyl]urea	
170	1-[(1R,5S,6R)-2,2-difluoro-6-bicyclo[3.1.0]hexanyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
171	1-[1-(3,3-difluorocyclobutyl)cyclopropyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
172	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,5S,6R)-2,2-difluoro-6-bicyclo[3.1.0]hexanyl]urea	
173	1-(2,2-difluorocyclopropyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
174	1-[(1S,5R,6S)-2,2-difluoro-6-bicyclo[3.1.0]hexanyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
175	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[1-(trifluoromethyl)cyclopropyl]urea	
176	1-[[2-(fluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,5S,6R)-2,2-difluoro-6-bicyclo[3.1.0]hexanyl]urea	
177	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[1-(3-fluoro-1-bicyclo[1.1.1]pentanyl)cyclopropyl]urea	




Example	Name	Structure
178	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[3-	





Example	Name	Structure
	(trifluoromethyl)-1-bicyclo[1.1.1]pentanyl]urea	
179	1-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
180	1-(4-fluoro-1-bicyclo[2.2.2]octanyl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
181	1-[(3,3-difluorocyclobutyl)methyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
182	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3-methyl-1-	






Example	Name	Structure
	bicyclo[1.1.1]pentanyl)urea	
183	1-[[2-(2-fluoropropoxy)pyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
184	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1S,2S)-2-hydroxy-2-methylcyclopentyl]urea	
185	1-[2-hydroxy-1-[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]ethyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
186	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3,4-	





Example	Name	Structure
	difluorophenyl)urea	
187	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,3S)-3-hydroxy-3-(trifluoromethyl)cyclopentyl]urea	
188	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3,3-dimethylcyclobutyl)urea	
189	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1R,3r,5S)-6,6-difluoro-3-bicyclo[3.1.0]hexanyl]urea	
190	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(2s,3aR,6aS)-	





Example	Name	Structure
	1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl]urea	
191	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[[1-(difluoromethyl)cyclobutyl]methyl]urea	
192	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3,4-dihydro-2H-chromen-3-yl)urea	
193	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,3S)-3-(difluoromethyl)cyclopentyl]urea	
194	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1r,3r)-1-methyl-3-	





Example	Name	Structure
	(trifluoromethyl)cyclobutyl]urea	
195	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(2r,3aR,6aS)-5,5-difluoro-2,3,3a,4,6,6a-hexahydro-1H-pentalen-2-yl]urea	
196	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,5R)-2-bicyclo[3.2.0]heptanyl]urea	
197	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,5S)-3,3-difluoro-8-bicyclo[3.2.1]octanyl]urea	





Example	Name	Structure
198	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1s,3s)-3-(trifluoromethyl)cyclobutyl]urea	
199	1-[[2-[(2R)-2-fluoropropoxy]pyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
200	1-[[2-(1,1-difluoroethyl)pyridin-4-yl]methyl]-3-(3-fluoro-1-bicyclo[1.1.1]pentanyl)urea	
201	1-[[2-(2,2-difluoropropoxy)pyridin-4-yl]methyl]-3-(3-fluoro-1-bicyclo[1.1.1]pentanyl)urea	





Example	Name	Structure
202	1-[[2-[(2S)-2-fluoropropoxy]pyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
203	1-(3-chlorophenyl)-3-[[2-(2,2,2-trifluoroethoxy)pyrimidin-4-yl]methyl]urea	
204	1-[[2-(2,2,2-trifluoroethoxy)pyrimidin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
205	1-(4-fluoro-3-methylphenyl)-3-[2-hydroxy-1-[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]ethyl]urea	
206	1-[[2-(difluoromethoxy)pyridin-4-	





Example	Name	Structure
	yl]methyl]-3-[(1R,3R)-3-(trifluoromethyl)cyclopentyl]urea	
207	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1S,3S)-3-(trifluoromethyl)cyclopentyl]urea	
208	1-(4-fluoro-1-bicyclo[2.2.2]octanyl)-3-[[2-(fluoromethoxy)pyridin-4-yl]methyl]urea	
209	1-[[2-(3,3-difluorocyclobutyl)oxypyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
210	1-[(1-fluorocyclobutyl)methyl]-3-[[2-(2,2,2-trifluoroethoxy)py	





Example	Name	Structure
	ridin-4-yl]methyl]urea	
211	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1s,4s)-4-(trifluoromethyl)cyclohexyl]urea	
212	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(2-trimethylsilylethyl)urea	
213	1-[[2-(2,3-difluoropropoxy)pyridin-4-yl]methyl]-3-(4-fluoro-1-bicyclo[2.2.2]octanyl)urea	
214	1-[[2-(2,3-difluoropropoxy)pyridin-4-yl]methyl]-3-[(1r,3r)-3-	





Example	Name	Structure
	(trifluoromethyl)cyclobutyl]urea	
215	1-[[6-(2,2,2-trifluoroethoxy)pyridazin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
216	1-[[2-(2,3-difluoropropoxy)pyridin-4-yl]methyl]-3-(3-fluoro-1-bicyclo[1.1.1]pentanyl)urea	
217	1-[[2-(2,2-difluoroethoxy)pyridin-4-yl]methyl]-3-(3-fluoro-1-bicyclo[1.1.1]pentanyl)urea	
218	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(6-methylpyridin-2-yl)urea	





Example	Name	Structure
219	1-[[2-(difluoromethoxy)-3-fluoropyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
220	1-(3-chlorophenyl)-3-[[2-(2,3-difluoropropoxy)pyridin-4-yl]methyl]urea	
221	1-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]-3-[[2-(1,1,1-trifluoropropan-2-yloxy)pyridin-4-yl]methyl]urea	
222	1-(7,7-difluoro-3-bicyclo[4.1.0]heptanyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
223	1-(3-fluoro-1-bicyclo[1.1.1]pentanyl)-3-[[2-(1,1,1-trifluoropropan-2-yloxy)pyridin-4-yl]methyl]urea	
224	1-[[2-(3,3-difluorocyclobutyl)oxypyridin-4-yl]methyl]-3-(3-fluoro-1-bicyclo[1.1.1]pentanyl)urea	
225	1-[[2-(2,3-difluoropropoxy)pyridin-4-yl]methyl]-3-[rac-(1R,3S)-3-(trifluoromethyl)cyclopentyl]urea	
226	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[2-(trifluoromethyl)oxan-4-yl]urea	






Example	Name	Structure
227	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1-fluorocyclopentyl)methyl]urea	
228	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(1,1,1,3,3,3-hexafluoropropan-2-yl)urea	
229	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[[1-(trifluoromethyl)cyclopropyl]methyl]urea	
230	1-[(1R)-1-(3,3-difluorocyclobutyl)-2,2-difluoroethyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
231	1-(3-chlorophenyl)-3-[[2-(1,1-difluoroethyl)pyridin-4-yl]methyl]urea	
232	1-[3-(fluoromethyl)phenyl]-3-[2-hydroxy-1-[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]ethyl]urea	
233	1-[2-hydroxy-1-[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]ethyl]-3-(3-methylphenyl)urea	
234	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(3R,4S)-3,4-difluorocyclopentyl]urea	





Example	Name	Structure
235	1-(3-cyclopropylcyclobutyl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
236	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2S,4S)-6,6-difluoro-2-bicyclo[2.2.1]heptanyl]urea	
237	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[[1-(trifluoromethyl)cyclobutyl]methyl]urea	
238	1-[(1R,3s,5S)-6,6-difluoro-3-bicyclo[3.1.0]hexanyl]-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	






Example	Name	Structure
239	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1S,3S)-3-fluorocyclopentyl]urea	
240	1-[1-[2-(difluoromethoxy)pyridin-4-yl]-2-hydroxyethyl]-3-(3,4-difluorophenyl)urea	
241	1-[(1R)-1-cyclobutyl-2,2,2-trifluoroethyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
242	1-[(1S)-1-cyclobutyl-2,2,2-trifluoroethyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
243	1-[[2-(difluoromethoxy)pyrimidin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
244	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(2,5-difluorophenyl)urea	
245	1-(2,5-difluorophenyl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
246	1-[1-(1-bicyclo[1.1.1]pentanyl)cyclopropyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
247	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(2,3-difluorophenyl)urea	
248	1-(2,3-difluorophenyl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
249	1-(3,4-difluorophenyl)-3-[[2-(fluoromethoxy)pyridin-4-yl]methyl]urea	
250	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1R,3S)-3-(trifluoromethyl)cyclohexyl]urea	
251	1-[dideuterio-[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(4-	





Example	Name	Structure
	fluoro-1-bicyclo[2.2.2]octanyl)urea	
252	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[3,3,3-trifluoro-2-(trifluoromethyl)propyl]urea	
253	1-(dicyclopropylmethyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
254	1-[1-(3,3-difluorocyclobutyl)cyclopropyl]-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
255	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2S)-2-	





Example	Name	Structure
	(trifluoromethyl)cyclobutyl]urea	
256	1-(3,5-difluorophenyl)-3-[2-hydroxy-1-[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]ethyl]urea	
257	1-[(1R)-1-cyclopropyl-2,2,2-trifluoroethyl]-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
258	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[5-(trifluoromethyl)oxolan-3-yl]urea	
259	1-(3-chlorophenyl)-3-[1-[2-(2,2-difluoroethoxy)pyridin-4-yl]-2-hydroxyethyl]urea	





Example	Name	Structure
260	1-[[2-(difluoromethylsulfanyl)pyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
261	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(4-fluoro-3-methylphenyl)urea	
262	1-[3-(difluoromethoxy)phenyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
263	rel-1-(3-chlorophenyl)-3-[(1R)-1-[2-(difluoromethoxy)pyridin-4-yl]-2-hydroxyethyl]urea	
264	1-[3-(difluoromethoxy)cyclopentyl]-3-[[2-	





Example	Name	Structure
	(difluoromethoxy) pyridin-4-yl]methyl]urea	
265	1-[(1s,3s)-3-(difluoromethoxy) cyclobutyl]-3-[[2-(difluoromethoxy) pyridin-4-yl]methyl]urea	
266	1-[(1r,4r)-4-(difluoromethoxy) cyclohexyl]-3-[[2-(difluoromethoxy) pyridin-4-yl]methyl]urea	
267	1-[[2-(difluoromethoxy) pyridin-4-yl]methyl]-3-[3-(trifluoromethoxy) cyclobutyl]urea	
268	1-[2-(difluoromethoxy) propyl]-3-[[2-(difluoromethoxy) pyridin-4-yl]methyl]urea	





Example	Name	Structure
269	1-((1s,3s)-3-fluorocyclobutyl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
270	1-(3-chloro-2-fluorophenyl)-3-[1-[2-(difluoromethoxy)pyridin-4-yl]-2-hydroxyethyl]urea	
271	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,5S,6R)-3,3-difluoro-6-bicyclo[3.1.0]hexanyl]urea	
272	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(2,3,4-trifluorophenyl)urea	



Example	Name	Structure
273	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(2S)-1,1,1,4,4,4-hexafluorobutan-2-yl]urea	
274	1-(3,4-difluorophenyl)-3-[[2-(2,2,2-trifluoroethyl)pyridin-4-yl]methyl]urea	
275	1-(3-chlorophenyl)-3-[[2-(2,2,2-trifluoroethyl)pyridin-4-yl]methyl]urea	
276	1-[rac-(1R,3S)-3-(trifluoromethyl)cyclohexyl]-3-[[2-(2,2,2-trifluoroethyl)pyridin-4-yl]methyl]urea	

Example	Name	Structure
277	1-[[2-(difluoromethoxy)-5-fluoropyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
278	1-[1-[2-(difluoromethoxy)pyridin-4-yl]-2-hydroxyethyl]-3-[(3S)-3,4-dihydro-2H-chromen-3-yl]urea	
279	1-[[6-(2,2,2-trifluoroethoxy)pyrimidin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
280	1-[1-[2-(difluoromethoxy)pyridin-4-yl]-2-hydroxyethyl]-3-(3-methylphenyl)urea	

Example	Name	Structure
281	1-[[2-(1,1,1-trifluoro-3-methoxypropan-2-yl)oxypyridin-4-yl]methyl]-3-[3-(trifluoromethyl)cyclobutyl]urea	
282	1-[[6-(difluoromethoxy)pyrimidin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
283	1-(3-fluoro-1-bicyclo[1.1.1]pentanyl)-3-[2-hydroxy-1-[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]ethyl]urea	
284	1-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]-3-[[1-(trifluoromethyl)cyclopropyl]methyl]urea	

Example	Name	Structure
285	1-(1,1,1,3,3,3-hexafluoropropan-2-yl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
286	1-[(2R)-1-[2-(difluoromethoxy)pyridin-4-yl]-2-hydroxypropyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
287	1-[(2S)-1-[2-(difluoromethoxy)pyridin-4-yl]-2-hydroxypropyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
288	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1R,3S)-3-(trifluoromethoxy)cyclopentyl]urea	


Example	Name	Structure
289	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[2-(3-fluoro-1-bicyclo[1.1.1]pentanyl)-2-hydroxyethyl]urea	
290	1-[2-(3-fluoro-1-bicyclo[1.1.1]pentanyl)-2-hydroxyethyl]-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
291	1-[2-(1-bicyclo[1.1.1]pentanyl)-2-hydroxyethyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
292	1-[2-(1-bicyclo[1.1.1]pentanyl)-2-hydroxyethyl]-3-[[2-(2,2,2-	

Example	Name	Structure
	trifluoroethoxy)pyridin-4-yl]methyl]urea	
293	1-[(1r,3r)-3-(difluoromethyl)cyclobutyl]-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
294	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(2R)-1,1,1,4,4,4-hexafluorobutan-2-yl]urea	


11. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 9,


- wherein R^1 is CHF_2O- and R^6 is substituted with one or two F-; and/or


- with the proviso that the compound is not one selected from:



,


,


, and


; and/or

- wherein such compounds of formula (I) show Kv7.2 EC_{50} <3μM and selectivity ratio Kv7.5_7.3/Kv7.2 >10x.

12. A pharmaceutical composition comprising the compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 11, wherein the pharmaceutical composition optionally further comprises one or more pharmaceutical excipients.

13. The pharmaceutical composition according to claim 12, wherein:

(i) the pharmaceutical composition comprises a compound of formula (I'), or a solvate or a pharmaceutically acceptable salt thereof, wherein:

Y^1, Y^2 are CH;

Y^3 is selected from CH or N;

R^1 is selected from a 4-6 membered heterocycloalkyl, cyano, haloC_{1-6}alkoxy, haloC_{1-6} alkylthio, C_{1-6}alkoxy, a 4-6 membered heterocyclyloxy, halogen, haloC_{1-6}alkyl, C_{3-5}cycloalkylC_{1-6}alkoxy, cyanoC_{1-6}alkoxy, and 5 membered heteroaryl; wherein the heterocycloalkyl, heterocyclyloxy, and heteroaryl are optionally substituted with one C_{1-6}alkyl, or haloC_{1-6}alkyl;

R^2 and R^3 are independently selected from hydrogen, and hydroxyC_{1-6}alkyl;

R^4 and R^5 are independently selected from hydrogen, a saturated monocyclic 3-5 membered cycloalkyl, haloC_{1-6}alkyl and C_{1-6}alkyl, or

R^4 and R^5 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;

R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, a 3-10 membered cycloalkyl, Si(C_{1-6}alkyl)$_3$ and phenyl, wherein the heterocycloalkyl, heteroaryl, cycloalkyl, or phenyl are optionally substituted with one, two, or three substituents independently selected from halogen, C_{1-6} alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, cyano, oxo, hydroxy, hydroxyC_{1-6}alkyl, haloC_{1-6}alkoxy, and haloC_{1-6}alkyl; and

n is 0, 1, 2, or 3; or

(ii) the pharmaceutical composition comprises a compound of formula (I'), or a solvate or a pharmaceutically acceptable salt thereof, wherein:

Y^1, Y^2 are CH;

Y^3 is selected from CH or N;

R^1 is selected from a 4-6 membered heterocycloalkyl, cyano, haloC_{1-6}alkoxy, haloC_{1-6} alkylthio, C_{1-6}alkoxy, a 4-6 membered heterocyclyloxy, halogen, haloC_{1-6}alkyl, C_{3-5}cycloalkylC_{1-6}alkoxy, cyanoC_{1-6}alkoxy, and 5 membered heteroaryl; wherein the heterocycloalkyl, heterocyclyloxy, and heteroaryl are optionally substituted with one C_{1-6}alkyl, or haloC_{1-6}alkyl;

R^2 and R^3 are independently selected from hydrogen, and hydroxyC_{1-6}alkyl;


R^4 and R^5 are independently selected from hydrogen, a saturated monocyclic 3-5 membered cycloalkyl, haloC_{1-6}alkyl and hydroxyC_{1-6}alkyl;

R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, a 3-10 membered cycloalkyl, Si(C_{1-6}alkyl)$_3$ and phenyl, wherein the heterocycloalkyl, heteroaryl, cycloalkyl, or phenyl are optionally substituted with one, two, or three substituents independently selected from halogen, C_{1-6} alkyl,


C_{3-6}cycloalkyl, C_{1-6}alkoxy, cyano, hydroxy, haloC_{1-6}alkoxy and haloC_{1-6}alkyl; and


n is 0, 1, or 2; or

(iii) the compound of formula (I') or (I) excludes compounds in which all of the following applies:

R^1 is 

,

R^6 is 

or 

,

n is 2, and R^4 and R^5 are (i) all hydrogen or (ii) within the first pair of R^4 and R^5 both are hydrogen and within the second pair of R^4 and R^5 one is hydrogen and the other one is hydroxy; or

(iv) the pharmaceutical composition comprises a compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, wherein R^6 is selected from a saturated monocyclic 3-6 membered cycloalkyl, a 7-10 membered bicycylic fused cycloalkyl, a 4-10 membered bridged cycloalkyl, a saturated monocyclic 3-6 membered cycloalkyl group, a 7-10 membered bicycylic fused cycloalkyl, phenyl, $Si(C_{1-6}alkyl)_3$ and a haloC_{1-6}alkyl; or

(v) the pharmaceutical composition comprises a compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, wherein R^6 is selected from a saturated monocyclic 3-6 membered cycloalkyl, a 7-10 membered bicycylic fused cycloalkyl, a 4-10 membered bridged cycloalkyl, a saturated monocyclic 3-6 membered cycloalkyl group, and a 7-10 membered bicycylic fused cycloalkyl.

14. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 11, or a pharmaceutical composition according to

claim 12 or 13, for use in the therapeutic and/or prophylactic treatment of a disorder, disease, or disability associated with Kv7.2 in a subject in need thereof, wherein the disorder, disease, or disability is selected from behavioral disorders, mood disorders, neurodevelopmental disorders, intellectual disability, epilepsies, neurodegenerative diseases, pain, migraine, and tinnitus.

15. The compound for use according to claim 14 or the pharmaceutical composition for use according to claim 14, wherein:

(i) the disorder, disease, or disability is a behavioral disorder which is Attention Deficit Hyperactivity Disorder (ADHD); or

(ii) the disorder, disease, or disability is a mood disorder which is depression; or

(iii) the disorder, disease, or disability is a neurodevelopment disorder selected from autism spectrum disorder (ASD) and syndromic developmental disorders; or

(iv) the disorder, disease, or disability is a syndromic developmental disorder selected from Dup15q syndrome (Dup15q), Fragile X syndrome (FXS) and Angelman syndrome; or

(v) the disorder, disease, or disability is an epilepsy selected from broad pediatric epilepsy, West syndrome, Ohtahara syndrome, and epileptic encephalopathy; or

(vi) the disorder, disease, or disability is a neurodegenerative disease selected from Alzheimer's disease, and motor neuron diseases;

optionally wherein the compound or the pharmaceutical composition is for systemic or local administration such as oral, nasal, parenteral (as by intravenous (both bolus and infusion), intramuscular, or subcutaneous injection), transdermal, vaginal, buccal, rectal, or topical administration modes, intracisternally, intraperitoneally, as an oral or nasal spray, or as a liquid aerosol or dry powder for inhalation.

16. A compound according to any one of claims 1 to 11, or a pharmaceutical composition according to claim 12 or 13, for use in therapy.

17. A kit for use in the therapeutic and/or prophylactic treatment of a disorder, disease, or disability associated with Kv7.2 comprising:


a) a compound according to any one of claims 1 to 11, or a pharmaceutical composition according to claim 12 or 13; and

b) instructions for use;


wherein the disorder, disease or disability is selected from behavioral disorders, mood disorders, neurodevelopmental disorders, intellectual disability, epilepsies, neurodegenerative diseases, pain, migraine, and tinnitus.

18. A process for the preparation of a compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 11, wherein:


(i) the urea formation comprises the reactions:




or



or




or



wherein R^1, R^2, R^3, n, R^4, R^5 and R^6 are as defined herein,

optionally wherein R^1 is selected from 7-12 membered heterocycloalkyl, cyano, halogen, haloC_{1-6}alkyl, and 5 membered heteroaryl; or


(ii) the process comprises the following reaction step:



wherein R^1, R^2, R^3, n, R^4, R^5 and R^6 are as defined herein,

optionally wherein R^1 is selected from haloC_{1-6}alkoxy, C_{1-6}alkoxy, 4-6 membered heterocyclyloxy, and C_{3-5}cycloalkylC_{1-6}alkoxy and R^2 and R^3 are hydrogen; or

(iii) the process comprises the reactions of the following reaction steps:



wherein R^1, R^2, R^3, n, R^4, R^5 and R^6 are as defined herein,

optionally wherein R^1 is selected from haloC_{1-6}alkoxy, C_{1-6}alkoxy, 4-6 membered heterocyclyloxy, C_{3-5}cycloalkylC_{1-6}alkoxy, or cyanoC_{1-6}alkoxy, and R^2 is hydroxyC_{1-6}alkyl and R^3 is hydrogen.